OptimizeRx's (OPRX) "Buy" Rating Reiterated at Stifel Nicolaus

OptimizeRx (NASDAQ:OPRX - Get Free Report)'s stock had its "buy" rating reiterated by Stifel Nicolaus in a research note issued to investors on Monday, Benzinga reports. They currently have a $13.00 target price on the stock. Stifel Nicolaus' price target would indicate a potential upside of 13.84% from the stock's current price.

Several other research analysts also recently weighed in on OPRX. Royal Bank of Canada reaffirmed an "outperform" rating and set a $17.00 target price on shares of OptimizeRx in a research note on Monday. Barclays began coverage on OptimizeRx in a research note on Wednesday, January 3rd. They set an "equal weight" rating and a $15.00 target price for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $16.00.

OptimizeRx Price Performance

NASDAQ:OPRX traded down $0.73 during trading hours on Monday, reaching $11.42. The company had a trading volume of 157,890 shares, compared to its average volume of 122,464. OptimizeRx has a 1-year low of $6.92 and a 1-year high of $16.65. The firm has a market cap of $207.30 million, a PE ratio of -14.33 and a beta of 1.01. The business's 50 day moving average price is $14.50 and its 200-day moving average price is $11.71.

Insider Buying and Selling

In related news, General Counsel Marion Odence-Ford sold 4,000 shares of the business's stock in a transaction that occurred on Tuesday, January 9th. The stock was sold at an average price of $15.19, for a total transaction of $60,760.00. Following the completion of the sale, the general counsel now directly owns 11,114 shares in the company, valued at $168,821.66. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.40% of the stock is owned by company insiders.

Institutional Trading of OptimizeRx

Several large investors have recently added to or reduced their stakes in OPRX. UBS Group AG grew its holdings in OptimizeRx by 290.0% in the 3rd quarter. UBS Group AG now owns 1,997 shares of the company's stock valued at $29,000 after buying an additional 1,485 shares in the last quarter. Nisa Investment Advisors LLC grew its holdings in OptimizeRx by 215.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,142 shares of the company's stock valued at $31,000 after buying an additional 1,462 shares in the last quarter. Captrust Financial Advisors grew its holdings in OptimizeRx by 248.8% in the 2nd quarter. Captrust Financial Advisors now owns 1,287 shares of the company's stock valued at $35,000 after buying an additional 918 shares in the last quarter. Quantbot Technologies LP purchased a new stake in OptimizeRx in the 3rd quarter valued at $49,000. Finally, Point72 Hong Kong Ltd purchased a new stake in OptimizeRx in the 1st quarter valued at $52,000. 76.47% of the stock is currently owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers (HCPs), and patients. Its products and applications include Evidence-Based Physician Engagement solution to assist HCPs in identifying patients who may be qualified for specific therapies, raise awareness of patient access pathways, and identify early indicators of non-adherence among patient populations; and Point of Care Banner messaging solution to deliver a variety of awareness and messaging within the clinical workflow.